NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

This is not just a run of the mill development project for a new cancer drug.
That has been done before, that process is well understood and it might be fair to criticize target dates that were missed even in a situation like this with many parties doing their utmost to ensure they fail.
This is a totally new paradigm. This has never been done before.
Anyone that been involved in development of a complex ground breaking technical project such as this knows that predicting time lines is not a easy thing to do and in the end it might not even be possible to do what is being attempted.
We heard on the video that many technical experts in the field thought they could design effective drugs to attacked a single or small number of cancer antegens, but are not understanding that our immune system does not work that way. It works instead by targeting large number of small differences in cancer antigens that vary widely from patient to patient.

Anyway back to your question. As we now understand more and more detail we can see that DCVAX is the right approach to this. It already appears that in phase-III it will be effect and hopefully approved soon for at least the Mesenchyma Subgroup patients and then with addition of PDL1 inhibitors may prove effect for even more cancers in the next wave of test. We can also now see why they delayed Direct because understanding this is import for Direct too.

Hope that Helps.